Biosimilars/News
Biosimilar infliximab launched in Japan
Japanese pharma firm Nippon Kayaku announced on 28 November 2014 the launch of its infliximab biosimilar, Infliximab BS, in Japan.
Biocad and Epirus to invest in follow-on biological products in Brazil
Biocad Russia is to open a US$40 million facility to produce three follow-on biological products in Brazil.
Momenta gains approval to start biosimilar adalimumab trial in Europe
US-based biotechnology firm Momenta Pharmaceuticals (Momenta) announced on 1 December 2014 the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a clinical trial application to initiate a clinical trial for its adalimumab biosimilar, M923.
Stada to in-license adalimumab biosimilar
German generics giant Stada Arzneimittel (Stada) announced on 18 November 2014 that it was in negotiations to in-licensing an adalimumab biosimilar.
Amgen expands biosimilars programme
Biologicals major Amgen is expanding its biosimilars portfolio to include nine different molecules.
Amgen launches biosimilars info app
Biologicals major Amgen has launched an app which aims to provide a source of information about biosimilars.
Amgen sues Sandoz over filgrastim biosimilar
Biologicals major Amgen is suing Sandoz to stop the biosimilars maker from marketing a biosimilar of its top-selling product Neupogen (filgrastim) in the US. Amgen claims in its lawsuit that Sandoz did not follow the rules for biosimilar development.
Study into switching from Aranesp to biosimilar epoetin alfa
Biologicals major Amgen has started recruiting patients for a clinical trial to study the effect of switching patients from the originator biological Aranesp (darbepoetin alfa) to biosimilar epoetin alfa, in other words, from a long-acting to a short-acting epoetin.
Coherus sells shares to raise funds for biosimilars programme
US-based biosimilars developer Coherus BioSciences (Coherus) is looking for further funding for its biosimilar programme. The company is preparing to sell shares in the company in order to raise funds to get three of the biosimilars in its pipeline through clinical trials.
Stada in-licenses teriparatide biosimilar
German generics giant Stada Arzneimittel (Stada) announced on 13 October 2014 that it had made a deal to in-licensing a teriparatide biosimilar.
